Insider · CIK 0001629383
Sarah Boyce
Files at RNA (Avidity Biosciences, Inc.), CTNM (Contineum Therapeutics, Inc.), RNA (Atrium Therapeutics, Inc.). First filing Dec 19, 2024, latest Jan 23, 2026.
Sarah Boyce files SEC Form 4 as CEO, president and director at RNA (Avidity Biosciences, Inc.), and also at CTNM (Contineum Therapeutics, Inc.), RNA (Atrium Therapeutics, Inc.). Since Dec 19, 2024, Sarah Boyce has reported 0 open-market buys worth $0 and 7 open-market sells worth $7.7M, the latest filed on Jan 23, 2026.
A track record needs three past buys with six months of prices behind them; Sarah Boyce has 0, so none is measured yet.
The newest scored trade: sold $1.0M of RNA on Jan 21, 2026, filed Jan 23, 2026, scored 45 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $1.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNA: Avidity Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Avidity Biosciences, Inc. | $1.0M 14,387 shares | -5% | - | |
| 40Moderate | Avidity Biosciences, Inc. | $619k 8,576 shares | -3% | - | |
| 35Weak | Avidity Biosciences, Inc. | $2.5M 50,000 shares | -14% | - | |
| 30Weak | Avidity Biosciences, Inc. | $1.2M 25,000 shares | -8% | - | |
| 45Moderate | Avidity Biosciences, Inc. | $980k 31,540 shares | -9% | - | |
| 34Weak | Avidity Biosciences, Inc. | $297k 10,397 shares | -3% | - | |
| 50Moderate | Avidity Biosciences, Inc. | $1.0M 31,855 shares | -11% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | 50,000 0.04% of outstanding | $2.4M | Sep 5, 2025 | $1.2M |
| Aug 28, 2025 | RNA AVIDITY BIOSCIENCES INC | 25,000 0.02% of outstanding | $1.2M | Aug 28, 2025 | none |
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | RNA Atrium Therapeutics, Inc. | FTax withholding Common Stock | -126,418 | $8.95 | $1.1M | 138,668 | 21 d ago |
| Jun 26, 2026 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 26, 2026 |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Mar 2, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -474,861 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -386,015 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -425,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -400,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -200,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -300,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -165,000 | - | - | 0 | Feb 27, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -6,394 | $72.45 | $463k | 277,000 | Jan 23, 2026 |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -7,993 | $72.45 | $579k | 269,007 | Jan 23, 2026 |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -8,576 | $72.23 | $619k | 283,394 | Jan 9, 2026 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +31,000 | $0.00 | $0 | 336,871 | Dec 19, 2025 |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | FTax withholding Common Stock | -15,742 | $71.87 | $1.1M | 321,129 | Dec 19, 2025 |
| Dec 18, 2025 | RNA Avidity Biosciences, Inc. | GGift Common Stock | -29,159 | $0.00 | $0 | 291,970 | Dec 19, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +50,000 | $1.24 | $62k | 355,871 | Sep 5, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -50,000 | $49.95 | $2.5M | 305,871 | Sep 5, 2025 |
| Sep 5, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 1,022,015 | Sep 5, 2025 |
| Aug 28, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +25,000 | $1.24 | $31k | 330,871 | Aug 29, 2025 |
| Aug 28, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $49.39 | $1.2M | 305,871 | Aug 29, 2025 |
| Aug 28, 2025 | RNA Avidity Biosciences, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 1,072,015 | Aug 29, 2025 |
| Jun 26, 2025 | CTNM Contineum Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +14,750 | $0.00 | $0 | 14,750 | Jun 26, 2025 |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -31,540 | $31.06 | $980k | 305,871 | Mar 21, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -4,738 | $28.59 | $135k | 343,070 | Jan 23, 2025 |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -5,659 | $28.59 | $162k | 337,411 | Jan 23, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +82,500 | $0.00 | $0 | 347,808 | Jan 8, 2025 |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +165,000 | $0.00 | $0 | 165,000 | Jan 8, 2025 |
| Dec 18, 2024 | RNA Avidity Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -31,855 | $32.66 | $1.0M | 265,308 | Dec 19, 2024 |
Questions about Sarah Boyce
Answered from the filings on this page, as of the latest one.
Is Sarah Boyce buying or selling?
In the last 12 months Sarah Boyce reported 0 open-market buys worth $0 and 2 open-market sells worth $1.7M on SEC Form 4; the latest was sold $1.0M of RNA on Jan 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Sarah Boyce's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sarah Boyce has 0.
Where does Sarah Boyce file Form 4?
Sarah Boyce has filed Form 4 at RNA (Avidity Biosciences, Inc.) as President and CEO; CTNM (Contineum Therapeutics, Inc.); RNA (Atrium Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.